W. Stuart

发表

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Michael Wall, J. Herbert, Jack H. Simon, 2002, Neurology.

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

M. Maguire, S. Galetta, G. Cutter, 2003, Neurology.

The Neurologist's Perspective: What Do We Know and Where Do We Go?

D. Bourdette, T. Vollmer, P. Ritvo, 1994 .

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

L. Kappos, C. Polman, P. Calabresi, 2009, Journal of Neurology.

Registry of Multiple Sclerosis Treatment and Care (MSTRAC) Patient and Physician Characteristics

L. Jacobs, T. Vartanian, J. Lacy, 2000 .

Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1)

David H. Miller, L. Kappos, C. Polman, 2009 .

A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta

Xingchang Wei, H. Weiner, R. Bakshi, 2005, Multiple sclerosis.

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.

F. Munschauer, W. Stuart, 1997, Clinical therapeutics.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

L. Kappos, C. Polman, P. Calabresi, 2009, Journal of Neurology.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS

Wynn, L. Kappos, C. Polman, 2005, Journal of the Neurological Sciences.

Methylprednisolone, Mycophenolate Mofetil, or Cyclophosphamide as Combination Therapy With Interferon Beta-1a in Patients With Multiple Sclerosis: Retrospective Study

W. Stuart, D. Court, J. Warth, 2007 .

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D. Goodin, D. Silberberg, F. Lublin, 2002, Neurology.

The incidence and significance of anti-natalizumab antibodies

D. Miller, L. Kappos, C. Polman, 2007, Neurology.